Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer (Q34320071)

1 August 2017

Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer (English)

1 reference

1 August 2017

Bas W G van Rhijn

1

1 reference

1 August 2017

1 July 2012

1 reference

1 August 2017

1 reference

1 August 2017

30

1 reference

1 August 2017

4

1 reference

1 August 2017

518-523

1 reference

1 August 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Epidemiology and genetic susceptibility to bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Bladder cancer: epidemiology, staging and grading, and diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Identifying distinct classes of bladder carcinoma using microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Genomics: a preview of genomic medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Pathological stage review is indicated in primary pT1 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.04.002

10.1016/J.UROLONC.2012.04.002

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

22742564